BECTON, DICKINSON AND COMPANY (BDX) Free cash flow
- Free cash flow · 12 months (USD): Value $3.20B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 14.25%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $3.20B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $3.96B − $753.00M ≈ $3.20B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 14.25% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $3.20B ÷ $22.48B × 100 ≈ 14.25% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $3.96B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 4.20× | Operating cash flow / net income. Period ending 2026-06-30. $3.96B ÷ $942.00M ≈ 4.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 3.96B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 753.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 3.20B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 22.48B USD | |
| Quarter-end shares | (m) | |
| Net income | 942.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.20B | (m) | $3.96B | $753.00M | (m) | $22.48B | (m) | $942.00M | (m) | (m) | 14.25% | 4.20× |
| 2026-03-31 | $3.50B | (m) | $4.27B | $774.00M | (m) | $22.23B | (m) | $1.14B | (m) | (m) | 15.72% | 3.75× |
| 2025-12-31 | $2.63B | (m) | $3.39B | $763.00M | (m) | $21.92B | (m) | $1.76B | (m) | (m) | 12.00% | 1.93× |
| 2025-09-30 | $2.67B | (m) | $3.43B | $760.00M | (m) | $21.84B | (m) | $1.68B | (m) | (m) | 12.23% | 2.04× |
| 2025-06-30 | $2.55B | (m) | $3.25B | $704.00M | (m) | $21.39B | (m) | $1.58B | (m) | (m) | 11.92% | 2.05× |
| 2025-03-31 | $2.62B | (m) | $3.33B | $709.00M | (m) | $20.87B | (m) | $1.50B | (m) | (m) | 12.57% | 2.22× |
| 2024-12-31 | $2.97B | (m) | $3.68B | $714.00M | (m) | $20.64B | (m) | $1.73B | (m) | (m) | 14.38% | 2.13× |
| 2024-09-30 | $3.12B | (m) | $3.84B | $725.00M | (m) | $20.18B | (m) | $1.71B | (m) | (m) | 15.46% | 2.25× |
| 2024-06-30 | $3.27B | (m) | $3.99B | $723.00M | (m) | $19.83B | (m) | $1.41B | (m) | (m) | 16.48% | 2.82× |
| 2024-03-31 | $3.04B | (m) | $3.77B | $735.00M | (m) | $19.72B | (m) | $1.33B | (m) | (m) | 15.42% | 2.83× |
| 2023-12-31 | $2.66B | (m) | $3.45B | $782.00M | (m) | $19.49B | (m) | $1.26B | (m) | (m) | 13.67% | 2.74× |
| 2023-09-30 | $2.12B | (m) | $2.99B | $874.00M | (m) | $19.37B | (m) | $1.48B | (m) | (m) | 10.92% | 2.01× |
| 2023-06-30 | $1.74B | (m) | $2.64B | $895.00M | (m) | $19.05B | (m) | $1.66B | (m) | (m) | 9.15% | 1.59× |
| 2023-03-31 | $980.00M | (m) | $1.94B | $957.00M | (m) | $18.81B | (m) | $1.62B | (m) | (m) | 5.21% | 1.20× |
| 2022-12-31 | $1.20B | (m) | $2.20B | $998.00M | (m) | $18.74B | (m) | $1.61B | (m) | (m) | 6.39% | 1.36× |
| 2022-09-30 | $1.50B | (m) | $2.47B | $973.00M | (m) | $18.87B | (m) | $1.78B | (m) | (m) | 7.94% | 1.39× |
| 2022-06-30 | $1.30B | (m) | $2.45B | $1.15B | (m) | $20.07B | (m) | $1.76B | (m) | (m) | 6.49% | 1.39× |
| 2022-03-31 | $1.90B | (m) | $3.04B | $1.15B | (m) | $20.03B | (m) | $1.92B | (m) | (m) | 9.47% | 1.58× |
| 2021-12-31 | $2.62B | (m) | $3.79B | $1.17B | (m) | $19.93B | (m) | $1.77B | (m) | (m) | 13.12% | 2.14× |
| 2021-09-30 | $3.42B | (m) | $4.65B | $1.23B | (m) | $20.25B | (m) | $2.09B | (m) | (m) | 16.87% | 2.22× |
| 2021-06-30 | $4.20B | (m) | $5.18B | $979.00M | (m) | $19.90B | (m) | $1.96B | (m) | (m) | 21.10% | 2.65× |
| 2021-03-31 | $4.15B | (m) | $5.06B | $914.00M | (m) | $18.86B | (m) | $1.72B | (m) | (m) | 22.00% | 2.95× |
| 2020-12-31 | $3.48B | (m) | $4.36B | $883.00M | (m) | $18.21B | (m) | $1.60B | (m) | (m) | 19.09% | 2.73× |
| 2020-09-30 | $2.73B | (m) | $3.54B | $810.00M | (m) | $17.12B | (m) | $874.00M | (m) | (m) | 15.94% | 4.05× |
| 2020-06-30 | $2.47B | (m) | $3.43B | $955.00M | (m) | $16.92B | (m) | $908.00M | (m) | (m) | 14.62% | 3.78× |
| 2020-03-31 | $2.51B | (m) | $3.50B | $990.00M | (m) | $17.41B | (m) | $1.07B | (m) | (m) | 14.41% | 3.25× |
| 2019-12-31 | $2.83B | (m) | $3.80B | $963.00M | (m) | $17.36B | (m) | $912.00M | (m) | (m) | 16.34% | 4.16× |
| 2019-09-30 | $2.37B | (m) | $3.33B | $957.00M | (m) | $17.29B | (m) | $1.23B | (m) | (m) | 13.72% | 2.70× |
| 2019-06-30 | $2.36B | (m) | $3.27B | $906.00M | (m) | $17.11B | (m) | $936.00M | (m) | (m) | 13.79% | 3.49× |
| 2019-03-31 | $2.01B | (m) | $2.88B | $866.00M | (m) | $17.04B | (m) | $1.08B | (m) | (m) | 11.79% | 2.67× |
| 2018-12-31 | $1.91B | (m) | $2.79B | $884.00M | (m) | $17.06B | (m) | $1.05B | (m) | (m) | 11.17% | 2.67× |
| 2018-09-30 | $1.97B | (m) | $2.87B | $895.00M | (m) | $15.98B | (m) | $311.00M | (m) | (m) | 12.33% | 9.21× |
| 2018-06-30 | $1.84B | (m) | $2.69B | $848.00M | (m) | $14.75B | (m) | $773.00M | (m) | (m) | 12.46% | 3.47× |
| 2018-03-31 | $1.68B | (m) | $2.53B | $846.00M | (m) | $13.50B | (m) | $47.00M | (m) | (m) | 12.45% | 53.77× |
| 2017-12-31 | $1.76B | (m) | $2.56B | $793.00M | (m) | $12.25B | (m) | $402.00M | (m) | (m) | 14.38% | 6.36× |
| 2017-09-30 | $1.82B | (m) | $2.55B | $727.00M | (m) | $12.09B | (m) | $1.10B | (m) | (m) | 15.07% | 2.32× |
| 2017-06-30 | $1.37B | (m) | $2.13B | $755.00M | (m) | $12.16B | (m) | $791.00M | (m) | (m) | 11.30% | 2.69× |
| 2017-03-31 | $1.87B | (m) | $2.58B | $707.00M | (m) | $12.32B | (m) | $1.31B | (m) | (m) | 15.19% | 1.96× |
| 2016-12-31 | $1.74B | (m) | $2.41B | $671.00M | (m) | $12.42B | (m) | $1.31B | (m) | (m) | 14.01% | 1.84× |
| 2016-09-30 | $1.87B | (m) | $2.56B | $693.00M | (m) | $12.48B | (m) | $976.00M | (m) | (m) | 14.95% | 2.62× |
| 2016-06-30 | $1.92B | (m) | $2.53B | $614.00M | (m) | $12.31B | (m) | $1.14B | (m) | (m) | 15.58% | 2.22× |
| 2016-03-31 | $1.63B | (m) | $2.24B | $602.00M | (m) | $12.23B | (m) | $810.00M | (m) | (m) | 13.36% | 2.76× |
| 2015-12-31 | $1.28B | (m) | $1.91B | $625.00M | (m) | $11.22B | (m) | $688.00M | (m) | (m) | 11.43% | 2.77× |
| 2015-09-30 | $1.13B | (m) | $1.73B | $596.00M | (m) | $10.28B | (m) | $695.00M | (m) | (m) | 11.03% | 2.49× |
| 2015-06-30 | $951.00M | (m) | $1.59B | $640.00M | (m) | $9.42B | (m) | $815.00M | (m) | (m) | 10.09% | 1.95× |
| 2015-03-31 | $862.00M | (m) | $1.49B | $630.00M | (m) | $8.46B | (m) | $1.08B | (m) | (m) | 10.19% | 1.38× |
| 2014-12-31 | $1.08B | (m) | $1.68B | $598.00M | (m) | $8.48B | (m) | $1.15B | (m) | (m) | 12.72% | 1.46× |
| 2014-09-30 | $1.15B | (m) | $1.75B | $592.00M | (m) | $8.45B | (m) | $1.19B | (m) | (m) | 13.66% | 1.47× |
| 2014-06-30 | $1.41B | (m) | $1.94B | $522.00M | (m) | $8.35B | (m) | (m) | (m) | (m) | 16.93% | (m) |
| 2014-03-31 | $1.40B | (m) | $1.94B | $539.00M | (m) | $8.24B | (m) | (m) | (m) | (m) | 17.03% | (m) |
| 2013-12-31 | $1.30B | (m) | $1.85B | $541.00M | (m) | $8.17B | (m) | (m) | (m) | (m) | 15.98% | (m) |
| 2013-09-30 | $1.20B | (m) | $1.72B | $522.00M | (m) | $8.05B | (m) | (m) | (m) | (m) | 14.84% | (m) |
| 2013-06-30 | $1.03B | (m) | $1.55B | $512.97M | (m) | $7.92B | (m) | (m) | (m) | (m) | 13.05% | (m) |
| 2013-03-31 | $1.19B | (m) | $1.66B | $473.26M | (m) | $7.85B | (m) | (m) | (m) | (m) | 15.15% | (m) |
| 2012-12-31 | $1.16B | (m) | $1.62B | $465.40M | (m) | $7.78B | (m) | (m) | (m) | (m) | 14.87% | (m) |
| 2012-09-30 | $1.21B | (m) | $1.69B | $487.43M | (m) | $7.71B | (m) | (m) | (m) | (m) | 15.64% | (m) |
| 2012-06-30 | $1.22B | (m) | $1.73B | $511.30M | (m) | $7.97B | (m) | (m) | (m) | (m) | 15.29% | (m) |
| 2012-03-31 | $1.08B | (m) | $1.62B | $536.21M | (m) | $7.94B | (m) | (m) | (m) | (m) | 13.59% | (m) |
| 2011-12-31 | $1.02B | (m) | $1.56B | $539.20M | (m) | $7.87B | (m) | (m) | (m) | (m) | 12.91% | (m) |
| 2011-09-30 | $1.20B | (m) | $1.71B | $515.38M | (m) | $7.83B | (m) | (m) | (m) | (m) | 15.29% | (m) |
| 2011-06-30 | $1.19B | (m) | $1.72B | $531.60M | (m) | $7.65B | (m) | (m) | (m) | (m) | 15.52% | (m) |
| 2011-03-31 | $1.22B | (m) | $1.72B | $503.16M | (m) | $7.47B | (m) | (m) | (m) | (m) | 16.27% | (m) |
| 2010-12-31 | $1.25B | (m) | $1.76B | $506.35M | (m) | $7.35B | (m) | (m) | (m) | (m) | 17.03% | (m) |
| 2010-09-30 | $1.12B | (m) | $1.66B | $537.31M | (m) | $7.37B | (m) | (m) | (m) | (m) | 15.22% | (m) |
| 2010-06-30 | $1.27B | (m) | $1.84B | $567.02M | (m) | $7.54B | (m) | (m) | (m) | (m) | 16.86% | (m) |
| 2010-03-31 | $1.26B | (m) | $1.86B | $597.68M | (m) | $7.48B | (m) | $1.27B | (m) | (m) | 16.83% | 1.46× |
| 2009-12-31 | $1.21B | (m) | $1.82B | $607.30M | (m) | $7.36B | (m) | $1.24B | (m) | (m) | 16.49% | 1.47× |
| 2009-09-30 | $1.10B | (m) | $1.69B | $591.10M | (m) | $7.16B | (m) | $1.23B | (m) | (m) | 15.37% | 1.37× |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | $1.06B | (m) | $1.66B | $601.68M | (m) | $7.07B | (m) | $1.13B | (m) | (m) | 15.02% | 1.48× |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-09-30 | $673.66M | (m) | $1.23B | $556.29M | (m) | $6.28B | (m) | $890.03M | (m) | (m) | 10.72% | 1.38× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |